These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21677914)

  • 21. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 22. Arsenic trioxide in the management of acute promyelocytic leukaemia.
    Mathews V; Chandy M; Srivastava A
    Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
    Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
    Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
    [No Abstract]   [Full Text] [Related]  

  • 25. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 27. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
    Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

  • 31. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 33. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
    Müller E; Seidel MG; Lackner H; Dworzak M; Urban C
    Klin Padiatr; 2013 May; 225(3):172-3. PubMed ID: 23625686
    [No Abstract]   [Full Text] [Related]  

  • 35. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
    Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N
    Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614
    [No Abstract]   [Full Text] [Related]  

  • 36. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
    Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
    Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
    Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes zoster during treatment with arsenic trioxide.
    Lanska DJ
    Ann Hematol; 2004 Jun; 83(6):408. PubMed ID: 15034759
    [No Abstract]   [Full Text] [Related]  

  • 40. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
    Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
    Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.